Organovo Holdings Inc
ONVO2.040USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
34.95MMarket Cap
LossP/E TTM
More Details of Organovo Holdings Inc Company
Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
Organovo Holdings Inc Info
Ticker SymbolONVO
Company nameVivoSim Labs Inc
IPO dateAug 02, 2013
CEO- -
Number of employees12
Security typeOrdinary Share
Fiscal year-endAug 02
AddressSuite 100
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92121
Phone18582241000
Websitehttps://organovo.com/
Ticker SymbolONVO
IPO dateAug 02, 2013
CEO- -
Company Executives of Organovo Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Executive Chairman of the Board, Corporate Secretary
Executive Chairman of the Board, Corporate Secretary
12.09K
--
Mr. Douglas Jay Cohen
Mr. Douglas Jay Cohen
Lead Independent Director
Lead Independent Director
5.90K
--
Ms. Alison Tjosvold Milhous
Ms. Alison Tjosvold Milhous
Independent Director
Independent Director
4.90K
--
Mr. Tony Lialin
Mr. Tony Lialin
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Adam K. Stern
Mr. Adam K. Stern
Independent Director
Independent Director
--
--
Mr. Norman Staskey
Mr. Norman Staskey
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. David Gobel
Mr. David Gobel
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Executive Chairman of the Board, Corporate Secretary
Executive Chairman of the Board, Corporate Secretary
12.09K
--
Mr. Douglas Jay Cohen
Mr. Douglas Jay Cohen
Lead Independent Director
Lead Independent Director
5.90K
--
Ms. Alison Tjosvold Milhous
Ms. Alison Tjosvold Milhous
Independent Director
Independent Director
4.90K
--
Mr. Tony Lialin
Mr. Tony Lialin
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Adam K. Stern
Mr. Adam K. Stern
Independent Director
Independent Director
--
--
Mr. Norman Staskey
Mr. Norman Staskey
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
DRW Securities, LLC
2.59%
Two Sigma Investments, LP
1.59%
HRT Financial LP
1.21%
The Vanguard Group, Inc.
0.86%
Geode Capital Management, L.L.C.
0.69%
Other
93.07%
Shareholders
Shareholders
Proportion
DRW Securities, LLC
2.59%
Two Sigma Investments, LP
1.59%
HRT Financial LP
1.21%
The Vanguard Group, Inc.
0.86%
Geode Capital Management, L.L.C.
0.69%
Other
93.07%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.04%
Hedge Fund
1.63%
Individual Investor
1.07%
Investment Advisor/Hedge Fund
0.90%
Research Firm
0.02%
Other
90.34%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
70
131.99K
5.06%
-94.46K
2025Q2
71
69.71K
3.58%
-169.31K
2025Q1
79
132.57K
3.80%
-106.53K
2024Q4
81
2.82M
16.18%
-646.34K
2024Q3
79
2.75M
17.65%
-645.19K
2024Q2
83
2.52M
17.88%
+653.74K
2024Q1
82
1.08M
10.68%
-803.36K
2023Q4
86
1.15M
12.01%
-616.73K
2023Q3
88
929.99K
10.67%
-924.84K
2023Q2
95
1.00M
11.49%
-764.70K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
22.37K
0.86%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
14.10K
0.54%
+14.05K
+26511.32%
Jun 30, 2025
Murphy (Keith E)
12.09K
0.47%
+1.84K
+17.94%
Jul 01, 2025
BlackRock Institutional Trust Company, N.A.
11.82K
0.45%
-27.00
-0.23%
Jun 30, 2025
Cohen (Douglas Jay)
5.90K
0.23%
+1.63K
+38.21%
Jul 01, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 19, 2025
Merger
12→1
Mar 19, 2025
Merger
12→1
Mar 19, 2025
Merger
12→1
Mar 19, 2025
Merger
12→1
Aug 18, 2020
Merger
20→1
Aug 18, 2020
Merger
20→1
Date
Type
Ratio
Mar 19, 2025
Merger
12→1
Mar 19, 2025
Merger
12→1
Mar 19, 2025
Merger
12→1
Mar 19, 2025
Merger
12→1
Aug 18, 2020
Merger
20→1
Aug 18, 2020
Merger
20→1
Aug 18, 2020
Merger
20→1
Aug 18, 2020
Merger
20→1
FAQs
Who are the top five shareholders of Organovo Holdings Inc?
The top five shareholders of Organovo Holdings Inc are:
The Vanguard Group, Inc. holds 22.37K shares, accounting for 0.86% of the total shares.
UBS Financial Services, Inc. holds 14.10K shares, accounting for 0.54% of the total shares.
Murphy (Keith E) holds 12.09K shares, accounting for 0.47% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.82K shares, accounting for 0.45% of the total shares.
Cohen (Douglas Jay) holds 5.90K shares, accounting for 0.23% of the total shares.
The Vanguard Group, Inc. holds 22.37K shares, accounting for 0.86% of the total shares.
UBS Financial Services, Inc. holds 14.10K shares, accounting for 0.54% of the total shares.
Murphy (Keith E) holds 12.09K shares, accounting for 0.47% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.82K shares, accounting for 0.45% of the total shares.
Cohen (Douglas Jay) holds 5.90K shares, accounting for 0.23% of the total shares.
What are the top three shareholder types of Organovo Holdings Inc?
The top three shareholder types of Organovo Holdings Inc are:
DRW Securities, LLC
Two Sigma Investments, LP
HRT Financial LP
DRW Securities, LLC
Two Sigma Investments, LP
HRT Financial LP
How many institutions hold shares of Organovo Holdings Inc (ONVO)?
As of 2025Q3, 70 institutions hold shares of Organovo Holdings Inc, with a combined market value of approximately 131.99K, accounting for 5.06% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 1.48%.
What is the biggest source of revenue for Organovo Holdings Inc?
In --, the -- business generated the highest revenue for Organovo Holdings Inc, amounting to -- and accounting for --% of total revenue.
